Our Discoveries
Akt protein kinase pathway regulates key step in the initiation of cilia formation
CCR investigators have discovered that activating the Akt protein kinase pathway stabilizes the binding of the WDR44 protein to the Rab11 protein. This prevents Rab11 from binding to the Rabin8 protein, thereby blocking cilia formation. When Akt is inactive, though, Rab11 instead is bound by FIP3, enhancing its binding to Rabin8, which helps initiate cilia formation. Since abnormalities in cilia formation are associated with a number of types of cancer, these findings point to several potential targets for cancer therapy.
Read MoreBacterial compound targets cancer-promoting RNA
Screening more than 3,000 natural products identified a compound that stops the growth of cancer cells by targeting a growth-promoting microRNA.
Read MoreCyclophosphamide works in an unexpected way to curb graft-vs-host disease in mice
For years it has been assumed that cyclophosphamide helps reduce the severity of graft-versus-host disease by eliminating alloreactive T cells, but new evidence reveals a different reason.
Read MoreMajority of patients with advanced multiple myeloma respond to CAR T-cell therapy targeting an anti-B-cell maturation antigen in a phase I trial
A phase I clinical trial of 33 patients infused with a CAR T-cell therapy using T cells genetically engineered to express an anti-B-cell maturation antigen (BCMA) CAR showed that 85 percent of patients had the burden of their advanced multiple myeloma cut by half or more.
Read MoreHeritable mutations may indicate responsiveness to platinum chemotherapy in malignant mesothelioma
In a genetic analysis of 434 patients with malignant mesothelioma who had undergone platinum chemotherapy, those who carried heritable mutations in BAP1and other DNA repair genes had significantly longer overall survival than those without these mutations. The findings hint at personalized approaches to the disease.
Read MoreEnvelope glycoprotein mutations allow HIV-1 to escape antiretroviral therapy in a lab-based study
CCR investigators have discovered that HIV-1 can compensate for a variety of mutations that block its replication by acquiring mutations in the envelope glycoprotein. Because antiretroviral therapies work by inhibiting viral replication, these findings may have implications for HIV-1 drug resistance.
Read MoreMEK inhibitor selumetinib granted breakthrough designation by FDA to treat neurofibromatosis type 1 in pediatric patients
The U.S. Food and Drug Administration last week granted breakthrough therapy designation for the MEK 1/2 inhibitor selumetinib. The designation is for the treatment of pediatric patients aged three years and older with neurofibromatosis type 1 (NF1) symptomatic and/or progressive, inoperable plexiform neurofibromas (PN), a rare, incurable genetic condition.
Read MoreHarnessing T-cell “stemness” could enhance cancer immunotherapy
A new study led by Nicholas Restifo, M.D., Senior Investigator in CCR’s Surgery Branch, sheds light on one way tumors may continue to grow despite the presence of cancer-killing immune cells. The findings, published March 29, 2019, in Science, suggest a way to enhance the effectiveness of immunotherapies for cancer treatment.
Read MoreCCR researchers discover how protein translation disruptions can lead to cancer
A mutation in the gene U2AF1, which codes for a protein involved in cutting out key pieces of RNA, can also have widespread effects on the translation of messenger RNA into proteins. A close look at one affected protein, interleukin 8 (IL8), revealed increased production as a result of the mutation, leading to inflammation and cancer spread.
Read MoreDrug found effective in mice for uveal melanoma
Drugs that directly target the transcription factor YAP, which is associated with the growth of uveal melanoma, are too toxic to be used in patients. A new study in mice, however, finds a new, safe and effective way for targeting the YAP pathway.
Read More